# Market Madness: Oil Rises Amid Chaos! Newsy: Bud Fox's 3 Controversial Stocks of the Day Published: 2026-03-19T14:00:00.255Z Source: https://newsyai.com/edition/16cc7cfb-a210-4be8-b3db-f39342cfd082 Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md --- # Futures Fizzle-Fuck: Oil's Steady Schlong-Up, Microcap Moonshots & Massacre! **Premarket penis-pump tease**—**Dow futures -0.05% ~46,300**[[1]](https://www.benzinga.com/premarket)[[2]](https://stockanalysis.com/markets/premarket/), **S&P -0.9% ~5,949**[[1]](https://www.benzinga.com/premarket), **Nasdaq -0.6% ~26,614**[[1]](https://www.benzinga.com/premarket) as Iran dick-drama drags on—**WTI crude $96.67 +0.35%** steady amid supply squabbles.[[3]](https://www.marketwatch.com/investing/future/cl.1?gaa_at=eafs&gaa_n=AWEtsqcshSWQ8aAEYldoh_pTvdxIoMITNMVBbvMgyqs7uCspvAMurCTNAdR0&gaa_sig=jvGwKGp5ibWqW06t9xROfBKuVq9qxZ5UOrlv-Hx_ZaOYXHhl1BEk_cr067bZESV-tgQraqlwPI5GFU6e0Ctc0g%3D%3D&gaa_ts=69bc04f4) SER biotech boner blast, CHNR China cum-back, RVPH pharma flop-fest. Bulls balls-deep, bears bitch-slapping—my no-bullshit balls-out breakdown.[[1]](https://www.benzinga.com/premarket)[[2]](https://stockanalysis.com/markets/premarket/) --- ## 1) Serina Therapeutics (SER): “Polymer Pipeline Prick-Tease” vs “Dilution Dick-Suck Debacle” **Why it’s loud** **SER** exploding **+65% pre to $2.11** on monster volume (31M+ shares)—biotech polymer drug-delivery hype rocket-fuels the pump, but penny purgatory patterns scream short-squeeze or scam.[[1]](https://www.benzinga.com/premarket)[[2]](https://stockanalysis.com/markets/premarket/) **Bull case (drug dong-delivery domination)** Unique SER-4 polymer platform for sustained-release meds crushes big-pharma bottlenecks, pipeline teases oncology/long-actings in $100B+ injectables TAM—volume volcano signals insider jizz or trial whisper.[[4]](https://finance.yahoo.com/quote/SER)[[5]](https://www.nasdaq.com/market-activity/stocks/ser) **Bear case (biotech black-hole bum-rush)** Serial cash-burner with dilution diarrhea history, no fresh catalysts announced, microcap momentum = rug-pull rimjob in crowded polymer pile-on.[[6]](https://www.marketbeat.com/stocks/NYSEAMERICAN/SER/news) **My take, first principles (depot drug moat vs pump-and-dump porn)** Strip the syringe: Proprietary polymers solve half-life headaches better than PEG bullshit, Iran oil-irrelevant but vol favors risk-on rockets—sustainable if partnerships pop. **Dip buy $1.80-2.00**, **$3/$4 calls** squeeze squirt—**puts $1.50** fade fart. Risk: Newsless nosedive.[[1]](https://www.benzinga.com/premarket) --- ## 2) China Natural Resources (CHNR): “Commodity China Cumback” vs “Geo-Goblin Geopolitical Gangbang” **Why it’s loud** **CHNR** ripping **+48% pre to $4.88** (27M vol)—China resources miner rides oil/rare-earth rally amid Iran jizz-jam, reverse-split residue reignites reverse-pump debate.[[1]](https://www.benzinga.com/premarket)[[2]](https://stockanalysis.com/markets/premarket/) **Bull case (Middle Kingdom metal money-shot)** Oil spike juices coal/metal ops in Guangdong, China stimmy whispers + commodity supercycle = profit prick from $3.35 close—geobull thesis ignores tariff truce teases.[[7]](https://finance.yahoo.com/quote/CHNR)[[3]](https://www.marketwatch.com/investing/future/cl.1?gaa_at=eafs&gaa_n=AWEtsqcshSWQ8aAEYldoh_pTvdxIoMITNMVBbvMgyqs7uCspvAMurCTNAdR0&gaa_sig=jvGwKGp5ibWqW06t9xROfBKuVq9qxZ5UOrlv-Hx_ZaOYXHhl1BEk_cr067bZESV-tgQraqlwPI5GFU6e0Ctc0g%3D%3D&gaa_ts=69bc04f4) **Bear case (Dragon dick-flop destiny)** Past reverse-splits tanked harder, China crackdown + dilution dong = value-trap vampire in $5B micro-miner mess, Iran upside capped by supply flood.[[8]](https://www.stocktitan.net/news/CHNR) **My take, first principles (resource reclamation edge vs Xi's bitch-whip)** Core the coal: Undervalued assets in EV-metal frenzy ($200B TAM) escape China curse if oil >$100 holds—but reverse-split stench stinks. **Grab $4.20-4.50**, **$6/$7 calls** commodity cream—**puts $3.50** de-risk dump. Risk: Tariff titty-twist.[[1]](https://www.benzinga.com/premarket) --- ## 3) Reviva Pharmaceuticals (RVPH): “Brilaroxazine Brain-Boner” vs “Trial Tardiness Taint” **Why it’s loud** **RVPH** cratering **-53% pre to $0.88** (736K vol)—schizo/psych pipeline panic plunge post-data drought, bears feast on FDA fast-track fizzle.[[1]](https://www.benzinga.com/premarket)[[2]](https://stockanalysis.com/markets/premarket/) **Bull case (mental med moat masterstroke)** Brilaroxazine Phase 3 topline imminent for schizo (multi-receptor serotonin/dopa edge > Abilify ass), $1B+ TAM if endpoints hit—oversold overshoot on no-news dump.[[2]](https://stockanalysis.com/markets/premarket/) **Bear case (pharma flop factory)** Repeated delays, cash inferno ($50M burn), dilution deluge = biotech bust in crowded CNS cockfight (J&J/Pfizer pounders).[[9]](https://stockanalysis.com/markets/premarket/losers) **My take, first principles (serotonin symphony vs execution erectile dysfunction)** Peel the pill: Broad-spectrum 5HT1A/D2 agonist = best-in-class schizo slayer sans weight-gain wang, but trial tard balls ache. Blood in streets = buy. **Bottom-fish $0.75-0.85**, **$1.50/$2 calls** data dong—**puts $0.60** dud dickslap. Risk: Endpoint enema.[[1]](https://www.benzinga.com/premarket) --- ## Tape-Side Tactics (cock the chamber or chug the choke) - **SER**: **$1.80-2.00** polymer plug; **$3C/$4C** spreads, **P$1.50** pump puke.[[1]](https://www.benzinga.com/premarket) - **CHNR**: **$4.20-4.50** China chug; **$6C/$7C**, **P$3.50** geo-gank.[[2]](https://stockanalysis.com/markets/premarket/) - **RVPH**: **$0.75-0.85** pharma pity-fuck; **$1.50C/$2C**, **P$0.60** trial turd.[[1]](https://www.benzinga.com/premarket) Iran simmer or sizzle? Biotech bonanza or bust? DYOR, thrust or bust-nut.